Fossgreen J, Kirchheiner B, Petersen F O, Tophoj E, Zachariae E
Scand J Rheumatol Suppl. 1976;1976(0):93-8.
In a double-blind cross-over trial the clinical efficacy of ketoprofen (19.583 R.P., Orudis, Profenid N.D.), in comparison with that of indomethacin was investigated in 30 patients with rheumatoid arthritis. The two drugs were each given in a dosage of 150 mg daily for a period of 14 days. The clinical effects of ketoprofen and indomethacin were equal (p less than 0.90), but several side-effects appeared less often and to a milder degree during ketoprofen treatment. The study indicates that ketoprofen may prove to be a valuable drug in the treatment of rheumatoid arthritis.
在一项双盲交叉试验中，对30例类风湿性关节炎患者研究了酮洛芬（19.583 R.P.，奥鲁地，优洛芬，新制剂）与吲哚美辛相比的临床疗效。两种药物均每日服用150毫克，持续14天。酮洛芬和吲哚美辛的临床效果相当（p小于0.90），但在酮洛芬治疗期间，几种副作用出现的频率较低且程度较轻。该研究表明，酮洛芬可能被证明是治疗类风湿性关节炎的一种有价值的药物。
